NCT03013010CompletedPhase 3
PREACT Study: Locally Advanced Gastric Cancer, Chemoradiotherapy vs. Chemotherapy Followed by D2 Surgery and Adjuvant Chemotherapy
A Randomized, Controlled, Multicenter Study to Compare Preoperative Radiochemotherapy With Preoperative Chemotherapy in Patients With Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma (PREACT Study)
Source: ClinicalTrials.gov · Last updated 8 Dec 2025
Brief summary (registry, in English)
Although the incidence of gastric cancer has been substantially declining for several decades, it is still the sixth most common cancer and the fourth most frequent cause of cancer death worldwide. Surgery is still the only curative option for gastric cancer. However, most patients are unable to undergo surgery because of late stage, unresectable disease. The prognosis for these patients is very poor. Although the Magic trial showed that perioperative chemotherapy can increase the rate of curative surgery and significantly improve overall survival in patients with operable gastric or lower esophageal adenocarcinomas, no pCR events were reported in this trial. The intervention arm in PREACT consists of pre-operative chemotherapy, pre-operative radiochemotherapy, surgery and post-operative chemotherapy. The control arm consists of pre-operative chemotherapy, surgery, and post-operative chemotherapy. The primary purpose of PREACT is to investigate whether the addition of radiochemotherapy to chemotherapy is superior to chemotherapy alone in the pre-operative setting in improving disease free survival in patients with locally advanced gastric or esophagogastric junction adenocarcinoma.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 204 (actual)
- First submitted
- 4 Jan 2017
- Start date
- 1 Dec 2016
- Primary completion date
- 5 Dec 2024
- Lead sponsor
- Shanghai Cancer Hospital, China
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT03013010
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 204
- From 1 Dec 2016 to the primary completion date, 5 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior chemotherapy or radiotherapy
- Known history of uncontrolled or symptomatic angina, uncontrolled arrhythmias and hypertension, or congestive heart failure, or cardiac infarction within 6 months prior to study enrollment, or cardiac insufficiency
- Concurrent severe infection
- Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety
Other illness
- Evidence of metastatic disease
- Patients with a past history of cancer in the 5 years before randomization except for the squamous or basal cell carcinoma of the skin that has been effectively treated, and carcinoma in situ of the cervix that has been treated by operation
- Patients with other significant underlying medical conditions that may be aggravated by the study treatment or are not controlled
- Patients with central nervous system(CNS) disorder or peripheral nervous system disorder or psychiatric disease
- Severe gastrointestinal bleeding, gastrointestinal perforation
- Known hypersensitivity reaction or metabolic disorder to S-1or oxaliplatin
Lab values
- Renal impairment (GFR \<=50ml/min)
Other
- Pregnant or lactating females or female patients of childbearing potential who have not been surgically sterilized or are without adequate contraceptive measures
- Sexually active males or females refuse to practice contraception during the study until 30 days after end of study
- Unable to swallow
- Linitis plastica
Who the study is looking for
- Age \>=18 years
- Female and male
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Life expectancy \>=6 months
- Histologically proven adenocarcinoma of the stomach or gastroesophageal junction (GEJ) (excluding Siewert I) that is: Stage IIB (T3N1 only), IIIA (T2N3 not eligible), IIIB, and IIIC, i.e. T3 - T4a and node positive, or T4b and/ or node positive, according to American Joint Committee on Cancer (AJCC) 7th edition
- Considered operable following initial staging investigations or after pre-operative therapy Disease which can be radically treated with radiotherapy to 45 Gy with standard fractionation
- Adequate organ function defined as follows:
- Bone marrow: Haemoglobin \>=90 g/L, Absolute neutrophil count (ANC) \>=1.5 x 109 /L, Platelet count \>=100 x 109 /L; Hepatic: Serum bilirubin \<=1.5 x upper limit of normal, aspartate aminotransferase (AST) and/or alanine transaminase (ALT) \<=2.5 x upper limit of normal; Renal: Serum creatinine \<=1.0 x upper limit of normal
- Patients are willing to obey the treatment and provide blood and tissue specimens
- Written informed consent obtained before randomization
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fudan University Shanghai Cancer Center Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.